By ThinkSabio #ThinkSabio Latest News
Keros Therapeutics halts all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension
Subscribe
for ThinkSabio Updates !
We'll keep you up to date about our Stocks, Sec Alerts , Trendings Stocks etc..